Leonor M. Sarmento

TL;DR: The findings indicate that IL7R mutational activation is involved in human T-cell leukemogenesis, paving the way for therapeutic targeting of IL-7R–mediated signaling in T-ALL.

TL;DR: It is shown that PTEN is inactivated by small deletions affecting a few exons in 8% of pediatric T-ALL patients, and ongoing RAG activity may actively contribute to the acquisition of preleukemic hits, clonal diversification, and disease progression.

TL;DR: It is concluded that CHK1 is critical for T-ALL proliferation and viability by downmodulating replication stress and preventing ATM/caspase-3-dependent cell death.

TL;DR: The results show for the first time the existence of epigenetic regulation of TAL1 by specific miRNAs which may contribute, at least in part, to the ectopic expression of Tal1 in some T-ALL cases.

TL;DR: The latest advances in the development and use of Notch antagonists are reviewed and the current knowledge on Notch function in T-ALL is summarized to understand how it may translate into novel therapeutic strategies that increment the efficiency of notch inhibition.